NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3GlobeNewsWire • 08/15/23
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023GlobeNewsWire • 08/04/23
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced CancersGlobeNewsWire • 07/19/23
Nanobiotix surges on commercialization deal with J&J's Janssen for cancer therapeuticProactive Investors • 07/10/23
Nanobiotix ADRs Jump Over 50% After Agreement With J&J's Janssen PharmaceuticalInvestopedia • 07/10/23
Nanobiotix's stock soars after entering licensing, development deal with J&J's Janssen PharmaceuticaMarket Watch • 07/10/23
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3GlobeNewsWire • 07/10/23
Nanobiotix stock skyrockets on final negotiations with ‘major' drug maker for its cancer treatmentProactive Investors • 05/05/23
Nanobiotix stock more than triples, after biotech enters final negotiations with ‘major' drug maker on development of cancer treatmentMarket Watch • 05/05/23
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical CompanyGlobeNewsWire • 05/05/23
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial ResultsGlobeNewsWire • 04/24/23
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023GlobeNewsWire • 04/17/23
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023GlobeNewsWire • 03/14/23
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck CancerGlobeNewsWire • 12/27/22
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract StatementGlobeNewsWire • 12/21/22
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic CancerGlobeNewsWire • 11/14/22
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of CancerGlobeNewsWire • 11/10/22